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ABSTRACT
Plasmablastic lymphoma (PBL) is an aggressive lymphoma, often arising in the 
context of immunodeficiency and associated with Epstein-Barr virus (EBV) infection. 
The most frequently detected genetic alteration is the deregulation of MYC gene 
through the translocation - t(8;14)(q24;q32). The diagnosis of PBL is often challenging 
because it has an overlap in morphology, immunophenotype, cytogenetics and virus 
association with other lymphomas and plasma cell neoplasms; further, its molecular 
basis remains elusive. In the present study we aimed to better define the possible 
contribution of EBV infection as well as miRNA deregulation in PBL pathogenesis.
We studied 23 cases of PBL, 19 Burkitt lymphomas (BL), and 17 extra-medullary 
plasmacytoma (EMPC). We used qPCR and immunohistochemistry to assess 
EBV latency patterns, while micro-RNA (miRNA) profiling was performed by next 
generation sequencing (Illumina) and validated by qPCR. 
Our analysis revealed a non-canonical EBV latency program with the partial 
expression of some proteins characterizing latency II and the activation of an abortive 
lytic cycle. Moreover, we identified miRNA signatures discriminating PBL from BL 
and EMPC. Interestingly, based on the miRNA profile, PBL appeared constituted by 
two discrete subgroups more similar to either BL or EMPC, respectively. This pattern 
was confirmed in an independent set of cases studied by qPCR and corresponded to 
different clinico-pathological features in the two groups, including HIV infection, MYC 
rearrangement and disease localization. 
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INTRODUCTION 
Plasmablastic lymphoma (PBL) is a rare highly 
aggressive lymphoma that occurs most often in the 
context of Human Immunodeficiency Virus (HIV)-
infection (40-50%), or in other settings of decreased 
immune surveillance [1]. Tumor cells have a well-
defined morphology resembling B-immunoblasts, 
and express plasma cells markers [1]. However, a 
more or less pronounced plasmacytic differentiation 
as well as a variable expression of CD20 and PAX-
5 can be encountered [2]. Therefore, the diagnosis 
of PBL is challenging because it has an overlap in 
cytomorphologic and immunophenotypic features with 
plasma cell neoplasms and with lymphomas that show 
blastic appearance (i.e. more immature, plasmablast-
like morphology) [3]. Even using a comprehensive 
panel of immunostains, a confident differential 
diagnosis between PBL and anaplastic or plasmablastic 
extramedullary plasmacytoma (EMPC) is not always 
possible. Nonetheless, a proper distinction of these 
entities is mandatory as EMPC and PBL have different 
prognoses and currently benefit from different therapeutic 
strategies. On the other hand, the differential diagnosis 
between PBL and other lymphoma types with blastic 
appearance is often straightforward due to the lack of 
B-cell marker expression in PBL. However, BL shares 
numerous biologic similarities with PBL. In fact, the most 
frequently detected genomic alteration in PBL is t(8;14)
(q24;q32) leading to MYC/IGH rearrangement observed 
in about 50% of cases [1, 3]. Other overlaps include cell 
morphology with the starry sky appearance, the high 
proliferation rate, the MYC protein over-expression and 
the association with EBV infection. 
A common feature is the presence of the Epstein-
Barr virus (EBV) DNA in tumor cells in 50 to 75% of 
cases, with higher frequency in HIV-positive cases [1, 
3]. The molecular and genetic mechanisms underlying 
PBL pathogenesis remain largely unknown and are likely 
dependent on the complexity of biological interplays 
between immunodeficiency, molecular events (MYC 
gene rearrangements), co-infecting oncogenic viruses 
(EBV) [4] and chronic immune activation (expression of 
immune-checkpoint proteins) [5]. It is unknown, however, 
whether MYC translocation represents the initiating or a 
late genetic event in PBL pathogenesis, and furthermore 
the latency program of EBV in neoplastic cells is still 
debated. In fact, although the type I latency is commonly 
detected, type III latency can be observed in patients with 
HIV infection and in those patients with post-transplant 
PBL [3]. 
In the present study we aimed to better define 
the pathogenesis and molecular features of PBL by 1) 
assessing the EBV latency patterns in PBL by qPCR and 
immunohistochemistry; 2) performing, for the first time to 
the best of our knowledge, an unbiased miRNA profiling 
of PBL, EMPC, and BL by next generation sequencing 
(NGS). 
RESULTS 
qPCR and immunohistochemistry reveal a non-
canonical latency type and an abortive lytic cycle 
of EBV in plasmablastic lymphoma
We checked the expression of EBNA-1, EBNA-2, 
EBNA-3, LMP-1, LMP-2A, EBER transcripts, BZLF-1/
ZEBRA, BMRF-1/Ea-D, BHRF-1/Ea-R, BLLF1/gp350 
across the 13 PBL cases (12 EBV-positive and 1 EBV-
negative). EBNA-1 was detected in 12/13 cases (92.3%), 
LMP-1 and LMP-2 in 1/13 and 10/13 (7.7% and 76.9%, 
respectively) (Figure 1), EBNA-2 and EBNA-3 in 0/13, 
and EBER in 12/13 (92.3%). BZLF-1/ZEBRA was found 
in 12/13 cases (92.3%) and both BMRF-1/Ea-D e BHRF-
1/Ea-R in 10/13 (76.9%) (Figure 1), while none of the 
cases expressed BLLF1/gp350 (Figure 1). 
We then determined the expression of all the 
corresponding encoded-proteins. Immunohistochemistry 
(IHC) confirmed the non-canonical latency associated 
program with the partial expression of some proteins 
characterizing latency II (i.e. LMP-1 in 1/13 and LMP-
2 in 6/13 of the cases) (Figure 1). There was also the 
expression of proteins characterizing the lytic phase of 
the virus (i.e. BZLF-1/ZEBRA in 12/13, and BHRF-1/
Ea-R and BMRF-1/Ea-D in 9/13 of the cases) (Figure 1). 
BLLF1/gp350 was not detected in any case. The qPCR 
data substantially corresponded to those obtained by IHC; 
however, slight differences emerged likely due to the 
higher sensitivity of qPCR.
The same analyses were then carried out in the 
validation cohort with substantially identical results 
(Figure 1; Table 3).
Together, these data indicate a non-canonical EBV-
latency pattern in PBL.
In conclusion, we uncovered for the first time 1) an atypical EBV latency program in 
PBL; 2) a miRNA signature distinguishing PBL from the closest malignant counterparts; 
3) the molecular basis of PBL heterogeneity.
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Plasmablastic lymphomas can be divided into two 
groups based on the miRNA profiling
First, we sought to investigate the relation of PBL 
with BL and EMPC as far as miRNA expression was 
concerned. When an unsupervised approach was used, 
namely PCA, PBL appeared relatively heterogeneous and 
was not clearly distinct from BL and EMPC, indicating 
some degree of similarity with both of them. To better 
determine the possible relation with these two tumors, we 
developed a miRNA expression-based cell type classifier 
to establish whether single PBL cases could be related to 
either one (or none) of the two (BL or EMPC). We found 
that 7 out of 13 cases were significantly closer to EMPC, 
5 out of 13 to BL, and 1 was not clearly classified (Figure 
2A-B, Table 4). By a supervised analysis, we identified 
136 cellular miRNA differentially expressed in the two 
new subgroups (Figure 2C; Table 5a and 5b): 123 were 
up-regulated in “EMPC-related” PBLs, while 13 were 
up-regulated in “BL-related” ones. Among others, the 
expression level of hsa-mir-192-5p, hsa-mir-1304-3p, hsa-
mir-148a-3p, hsa-miR-365-3p was studied by RT-qPCR as 
technical validation. We observed that these miRNA were 
up-regulated in the cases belonging to the EMPC-related 
cluster and down-regulated in the BL-related samples, 
confirming NGS results (Figure 2D). Interestingly, the 
two groups of PBLs tended to differ also for some clinical 
features. The patients BL-related were younger (mean age: 
50.2 years), with a slight male predominance (M:F= 3:2), 
an extra-oral localization and a blastic appearance; the 
majority of them (4 out 5) were HIV-negative. The patients 
EMPC-related were older (mean age: 56.85 years), mainly 
male (M:F= 6:1), with an oral localization (4 out 7) and a 
more pronounced plasmacytic differentiation; the majority 
of them (4 out 7) were HIV-positive. Of note, 5/5 BL-
related cases presented with MYC rearrangements at FISH, 
while only 2/7 EMPC presented with such feature (fisher 
exact test, p=0.03). 
When we applied the cell classifier based on the 
expression of hsa-mir-192-5p, hsa-mir-1304-3p, hsa-
mir-148a-3p, hsa-miR-365-3p to an independent set 
of 10 cases, we found that 3/9 cases were classified as 
EMPC-related and 6/9 as BL-related, one case not 
being evaluable for technical reasons (qPCR failure) 
(Supplementary Figure 1). Noteworthy, training and test 
set were comparable concerning HIV infection (6/13 vs 
2/10, Fisher exact test, p=0.09)
Plasmablastic lymphomas and plasmacytomas 
have different miRNA profiles 
In order to unveil specific differences between the 
PBL and EMPC, we compared the two diseases in term 
of miRNA expression. When unsupervised approach was 
adopted, both principal component analysis (PCA) and 
hierarchical clustering (HC) failed to clearly separate 
the two entities (data not shown). Then, by supervised 
analysis, we identified 48 differentially expressed miRNA, 
including 38 EBV-encoded and 10 cellular miRNA which 
could clearly differentiate the two groups when PCA and 
HC methods were applied (Figure 3A-3B, Supplementary 
Table 2).  Of note, a linear discriminant analysis indicated 
Figure 1: RT-qPCR and immunohistochemistry reveal a non-canonical latency type and an abortive lytic cycle of EBV 
in neoplastic cells. LMP-2A A., E., BZLF-1/ZEBRA B., F.,  BMRF-1/Ea-D C., G., BHRF-1/Ea-R D., H., expression by RT-qPCR (across 
the 13 PBL cases) and immunohistochemistry (in one exemplificative PBL case; original magnification, 40x). In qPCR graphs, y-axis 
represents gene expression values (2 Delta Ct formula).
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Table 1: Clinical, histologic, immunophenotypic and FISH features of discovery cohort patients
 Discovery cohort Validation cohort
 PBL EMPC BL PBL EMPC BL
Mean age (range), 
years 54.2 (28-76) 65.2 (44-76) 17.7 (3-40) 66.3 (45-87) 59 (45-74) 18.3 (5-43)
Male:female ratio 10/3 5/2 4/5 7/3 5/2 (3NA) 3/6
Oral 5 1 1 1 1 1
Extra-Oral 8 (vulva, ileum, pleura, penis, skin)
6 (stomach, pleura, 
chest-wall, scrotum, 
vertebra)
8 (lymph-nodes, 
stomach, ileum, 
uterus, ovary)
9 (Ileum, stomach, 
thyroid, chest-wall, 
lymph-node, colon)
9 (iliac bone, 
chest-wall, 
lymph-node, 
vertebra)
8 (ileum, 
stomach, lymph-
nodes)
Morphology
blastic versus 
more pronounced 
plasmacytic 
differentiation; 
necrosis, mitotic 
figures and 
apoptotic bodies 
with a “starry-sky” 
appearance
proliferation of 
mature plasma cells; 
3 cases more blastic 
appearance, 1 case 
anaplastic
medium-sized cells, 
with monotonous and 
uniform appearance, 
squared-off 
cytoplasm, cohesive 
growth and starry-sky 
appearance
blastic versus 
more pronounced 
plasmacytic 
differentiation; 
necrosis, mitotic 
figures and apoptotic 
bodies with a “starry-
sky” appearance
proliferation of 
mature plasma 
cells; 3 cases 
more blastic 
appearance, 1 
case anaplastic
medium-sized 
cells, with 
monotonous 
and uniform 
appearance, 
squared-off 
cytoplasm, 
cohesive growth 
and starry-sky 
appearance
Immunophenotype       
CD38 13 9 9 10 10 9
CD138 13 9 0 10 10 -
IRF4/MUM1 13 - 0 10 - -
BCL2 13 (weak) - 0 10 (weak) - 0
BCL6 13 (weak) 0 9 10 (weak) - 9
CD10 13 (weak) 0 9 10 (weak) - 9
CD20 0 0 9 0 0 9
PAX5 0 0 9 0 0 -
HHV8 0 - - 2 - -
ALK1 0 - - 0 - -
CD56 1 - - - - -
MYC (20-50%) 0 2 0 0 - 0
MYC (>50%) 5 0 0 7 - 0
MYC (>80%) 8 0 9 2 - 9
MYC translocation 
(FISH) 8/13 2/7 9/9 9/10 2/10 9/9
EBV infection 12/13 2/7 5/9 4/10 0/10 6/9
Immune 
suppression 7/13 NA NA 2/10 NA NA
PBL: plasmablastic lymphoma; EMPC: extramedullary plasmacitoma; BL: Burkitt lymphoma; IHC: immunohistochemistry; 
pos.: positivity; neg.: negativity; NA.: not available.
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that as few as four miRNA (miR-665, miR-3613-5p, miR-
1304-3p and miR-3609) could correctly discriminate the 
samples. Accordingly, based on the expression of such 4 
miRNA, we generated a cell classifier and applied it to our 
series, being able to correctly classify all cases (overall 
accuracy 100%; Table 6; Figure 3C). The expression 
of these four miRNA was also validated by RT-qPCR 
in the same panel of cases, confirming NGS results 
(Supplementary Figure 2). Furthermore, for the potential 
diagnostic implication, we studied their expression by 
qPCR in an independent validation cohort, consisting of 
20 cases (10 PBL and 10 EMPC). When the cell classifier 
was applied, 9/10 EMPC and 10/10 PBL were correctly 
identified (95% overall accuracy; Supplementary Figure 
2; Table 7). All the three anaplastic EMPC included in the 
analysis were correctly classified. 
Plasmablastic lymphomas and Burkitt 
lymphomas have different miRNA profiles 
We then compared PBL to BL. By PCA the two 
diseases appeared relatively similar, without clear 
distinction (Figure 4A). By supervised analysis, we could 
identify a series of 42 differentially expressed miRNA (23 
cellular and 19 EBV miRNA) (Figure 4B, Supplementary 
Figure 2: Plasmablastic lymphomas include two molecular subgroups related to either EMPC or BL. Principal component 
analysis of plasmablastic lymphoma (PBL), extramedullary plasmacytoma (EMPC) and Burkitt lymphoma (BL) cases indicated a basic 
relation between the three entities at miRNA level A.. A cell type classifier based on a support vector machine algorithm was generated to 
discriminate BL and EMPC based on the expression of differentially expressed miRNA. When the algorithm was applied to PBL, they were 
classified as either BL or EMPC indicating their heterogeneity reflecting the similarity to either one of the other two tumor types (BL and 
EMPC) B.. Grey zone represent value below significance (0.05). Supervised analysis (t-test) comparing BL-related versus EMPC-related 
PBLs identified a series of differentially expressed genes C.. In the matrix, the dendrogram was generated using a hierarchical clustering 
algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour 
scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). 
Differential expression of hsa-miR-192-5p, hsa-miR-1304-3p, hsa-miR-148a-3p and hsa-miR-365-3p in BL-related versus EMPC-related 
PBLs group D.-G. Values are expressed as mean ± standard deviation (ST). Statistical significance was determined with Student’s unpaired 
t-test (p < 0.005).
Oncotarget107361www.impactjournals.com/oncotarget
Table 2: Primers’ sets used for qPCR analysis of EBV-encoded genes
Assay Primers set
EBNA1 
5’- TAC AGG ACC TGG AAA TGG CC- 3’ 
5’- TCT TTG AGG TCC ACT GCC G-3’ 
EBNA2 
5’-TAA CCA CCC AGC GCC AAT C-3’ 
5’- GTA GGC ATG ATG GCG GCA G 5’
EBNA3c 
5’- CTG GCA AAA CTT GCT CCA- 3’ 
5’- GTG CTT CTG CCT TAT CAG A- 3’
BHRF1 
5’-AGA AAC ACC TCT CCG CCT TT-3’
5’- ATC CAC ATG TTC GGT GTG TG-3’ 
LMP1 
5’- CAG TCA GGC AAG CCT ATG A-3’ 
5’- CTG GTT CCG GTG GAG ATG A-3’
BMRF1
5’- CAACACCGCACTGGAGAG- 3’ 
5’- GCCTGCTTCACTTTCTTGG- 3’ 
LMP2A
5’- AGC TGT AAC TGT GGT TTC CAT GAC-3’
5’- GCC CCC TGG CGA AGA G-3’ 
BLLF1 
5'-ATCCAGTTGTATTCAAGGTAGG-3'
5'-ACTCATTATCACACGAACGG-3'
 BZLF1 
 5’- AAA TTT AAG AGA TCC TCG TGT AAAACA TC-3’
5’- CGC CTC CTG TTG AAG CAG AT-3’
 HPRT 
5’-AGC CAG ACT TTG TTG GAT TTG-3’ 
5’-TTT ACT GGC GAT GTC AAT AAG-3’
Table 3: qPCR and immunohistochemical latency results on validation cohort
RT-qPCR IHC/ISH
Positive cases (n.) Negative cases (n.) Positive cases (n.) Negative cases (n.)
EBNA-1 4 6 n.p. n.p.
EBNA-2/3 0 10 n.p. n.p.
LMP-1 0 10 0 10
LMP-2 4 6 3 7
EBER - - 4 6
ZEBRA 3 7 4 6
EaR 4 6 3 7
EaD 4 6 3 7
gp350 0 10 0 10
ISH: in situ hybridization; n.: number of cases; n.p.: not performed
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Table 3). As technical validation, some of them (hsa-miR-
148-5p, hsa-miR-1273f, hsa-miR-4488, hsa-miR-494-3p; 
EBV-miR-BART10-3p, EBV-miR-BART18-3p and EBV-
miR-BART19-5p) were also evaluated by qPCR, that 
again confirmed NGS data (Figure 4C). With the exception 
of miR-148a-5p, all cellular miRNA were up-regulated in 
PBL cases in respect to BL samples; a higher expression 
of all viral miRNA was detected in BL in comparison to 
PBL group. 
These findings were also confirmed in our validation 
cohort (Supplementary Figure 3). 
Plasmablastic lymphomas differ in the miRNA 
profile based on HIV infection
Since the association with HIV might affect PBL 
miRNA profiling, we directly compared HIV-positive 
versus HIV-negative cases. Unsupervised evaluation 
by PCA was already able to distinguish the two groups 
(Figure 5A). Further, the supervised analysis identified as 
many as 68 differentially expressed miRNA all of which 
were of cellular origin and were up-regulated in the HIV-
positive group (Supplementary Table 4). By contrast, 
no EBV-encoded miRNA was differentially expressed. 
Based on the expression of such 68 miRNA, the cases 
were clearly distinct at HC (Figure 5B). None of the so 
far known HIV encoded miRNA emerged as significantly 
discriminating the two groups at NGS analysis. Therefore, 
in order to exclude possible underestimation of HIV-
encoded miRNA contribution, we used a more sensitive 
qPCR approach to investigate this issue further. Although 
at low level, we found that both the tested HIV-encoded 
miRNA (HIV-miR-N-367 and HIV-miR-TAR-3p) were 
expressed in HIV cases but not in the negative ones 
(Figure 5C-5D).
Figure 3: Plasmablastic lymphoma and extramedullary plasmacytoma are distinct based on the miRNA profile. 
Principal component analysis of plasmablastic lymphoma (PBL) and extramedullary plasmacytoma (EMPC) cases A.. Supervised analysis 
(T-test) comparing PBL and EMPC cases identified a series of differentially expressed genes B.. In the matrix B, the dendrogram was 
generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample 
and each row represents a gene. The colour scale bar shows the relative gene expression changes normalized by the standard deviation (0 is 
the mean expression level of a given gene). A cell type classifier based on a support vector machine algorithm was generated to discriminate 
PBL and EMPC based on the expression of differentially expressed miRNA C.. Grey zone represent value below significance (0.05). 
Differential expression of hsa-miR-665, hsa-miR-3613-5p, hsa-miR-1304-3p and hsa-miR-3609 in PBL versus EMPC group D.. Values are 
expressed as mean ± standard deviation (ST). Statistical significance was determined with Student’s unpaired t-test (p < 0.005).
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Table 4: Correlation between PBL and BL or EMPC
Identifier Cell type Predicted Confidence Measure 
H122 (raw) PBL BL 0.09583959
V109 (raw) PBL BL 0.10874487
s838 (raw) PBL BL 0.1592613
s613 (raw) PBL BL 0.20450206
s806 (raw) PBL BL 0.23559976
s1805 (raw) PBL EMPC 0.27476195
H276 (raw) PBL EMPC 0.45076987
s1529 (raw) PBL EMPC 0.4700034
s13725 (raw) PBL EMPC 0.47044697
s11224 (raw) PBL EMPC 0.5045746
s189 (raw) PBL BL 0.59934336
H333 (raw) PBL EMPC 0.6791907
V376 (raw) PBL EMPC 0.95444125
Figure 4: Plasmablastic lymphoma and Burkitt lymphoma are distinct based on the miRNA profile. Principal component 
analysis of plasmablastic lymphoma (PBL) and Burkitt lymphoma (BL) cases A.. Supervised analysis (t-test) comparing PBL and BL 
cases identified a series of differentially expressed genes B.. In the matrix B, the dendrogram was generated using a hierarchical clustering 
algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour 
scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). 
Cellular miRNA (hsa-miR-1273f, hsa-miR-148a-5p, hsa-miR-4488, hsa-miR-494-3p) and EBV-viral miRNA (EBV-miR-Bart10-3p, EBV-
miR-18-3p, EBV-miR-19-5p) expression in PBL versus BL cohort groups C.. Values are expressed as mean ± standard deviation (ST). 
Statistical significance was determined with Student’s unpaired t-test (p < 0.005).
Oncotarget107364www.impactjournals.com/oncotarget
Table 5A: miRNA differentially expressed in the two PBL groups (BL-related versus EMPC-related)
miRNA p Fold change
Regulation in 
BL-related 
group
hsa-let-7a-5p 0.028575 256 down
hsa-let-7b-5p 0.006063 10809.406 down
hsa-let-7d-3p 0.044231 2.6918004 down
hsa-let-7d-5p 0.012786 3.482202 down
hsa-let-7e-5p 0.028014 4.3297553 down
hsa-let-7f-5p 0.018527 159.15468 down
hsa-let-7g-5p 0.046021 13.387893 down
hsa-miR-101-3p 0.002134 48.502926 down
hsa-miR-103a-3p 0.004657 21.5344 down
hsa-miR-103b 0.011111 18.74678 down
hsa-miR-106b-3p 0.02385 4.594794 down
hsa-miR-106b-5p 0.025859 13.125367 down
hsa-miR-10b-5p 0.045394 1.17E+07 down
hsa-miR-125a-5p 0.022511 40.58451 down
hsa-miR-125b-1-3p 0.002118 2.6918004 down
hsa-miR-126-3p 0.012516 128 down
hsa-miR-126-5p 0.0226 159.15468 down
hsa-miR-127-3p 0.030994 86.13763 down
hsa-miR-128-3p 0.00253 8.659511 down
hsa-miR-1304-3p 0.039182 5.0730634 down
hsa-miR-130a-3p 0.015367 5.0730634 down
hsa-miR-130b-3p 0.024846 5.278032 down
hsa-miR-132-3p 0.003019 3.8446627 down
hsa-miR-139-5p 0.037432 2.122426 down
hsa-miR-140-3p 0.004751 436.9814 down
hsa-miR-140-5p 0.038232 2.164878 down
hsa-miR-143-3p 0.023024 40743.586 down
hsa-miR-145-3p 0.034978 4.780439 down
hsa-miR-145-5p 0.019368 26.250734 down
hsa-miR-146a-5p 0.002346 111.43049 down
hsa-miR-146b-5p 0.003099 1176.267 down
hsa-miR-148a-3p 0.003072 1.38E+10 down
hsa-miR-148b-3p 0.001742 13.387893 down
hsa-miR-151a-3p 0.017852 49.47307 down
hsa-miR-155-5p 0.042635 62.74499 down
hsa-miR-15a-5p 0.01427 4.9735837 down
hsa-miR-15b-5p 0.029421 3.0920668 down
hsa-miR-16-5p 0.002014 5967.2734 down
hsa-miR-181a-3p 0.00621 2.390219 down
hsa-miR-181a-5p 0.003179 26353.643 down
hsa-miR-181b-5p 0.028867 218.4907 down
hsa-miR-181c-5p 0.024008 5.0730634 down
hsa-miR-182-5p 0.041277 141.3235 down
hsa-miR-183-5p 0.017472 34.638054 down
hsa-miR-186-5p 0.006628 182.82076 down
hsa-miR-191-5p 0.003595 6854.601 down
hsa-miR-192-5p 0.003457 10.146127 down
hsa-miR-193b-3p 0.003606 179.23567 down
hsa-miR-195-5p 0.037465 3.3469734 down
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miRNA p Fold change
Regulation in 
BL-related 
group
hsa-miR-196a-5p 0.033883 9.373392 down
hsa-miR-197-3p 0.02192 13.387893 down
hsa-miR-199a-3p 0.043553 8.489703 down
hsa-miR-210-3p 0.020199 5.1745324 down
hsa-miR-2110 0.020158 2 down
hsa-miR-212-3p 0.037432 2.122426 down
hsa-miR-21-3p 0.027591 25.73597 down
hsa-miR-214-3p 0.016095 5.1745324 down
hsa-miR-21-5p 0.016598 1.60E+09 down
hsa-miR-221-3p 0.009039 194.0117 down
hsa-miR-221-5p 0.019567 3.482202 down
hsa-miR-222-3p 0.001477 120.616684 down
hsa-miR-22-3p 0.021866 144.15012 down
hsa-miR-23a-3p 0.008328 48.502926 down
hsa-miR-23b-3p 0.03084 48.502926 down
hsa-miR-24-3p 0.047314 13.655676 down
hsa-miR-25-3p 4.42E-04 324.6761 down
hsa-miR-26a-5p 0.006917 8693.463 down
hsa-miR-26b-5p 8.58E-04 93.23874 down
hsa-miR-27a-3p 0.011841 1176.267 down
hsa-miR-27b-3p 0.011343 512 down
hsa-miR-27b-5p 0.048211 2 down
hsa-miR-28-3p 0.001606 50.4626 down
hsa-miR-28-5p 7.68E-04 6.0628657 down
hsa-miR-29b-3p 0.012198 5.6011167 down
hsa-miR-29c-3p 0.004106 7.3907156 down
hsa-miR-29c-5p 0.001043 3.482202 down
hsa-miR-301a-3p 0.00456 4.504692 down
hsa-miR-3074-5p 0.00282 5.3836007 down
hsa-miR-30a-5p 0.028991 70.66175 down
hsa-miR-30b-5p 0.006546 7.1037035 down
hsa-miR-30c-5p 0.003975 15.686253 down
hsa-miR-30d-5p 0.020276 86.13763 down
hsa-miR-30e-3p 0.009217 5.6011167 down
hsa-miR-30e-5p 0.012316 231.86519 down
hsa-miR-3184-3p 0.036321 3.8446627 down
hsa-miR-3184-5p 0.047828 29.562862 down
hsa-miR-324-5p 0.007311 2.8565736 down
hsa-miR-326 0.017578 2.6918004 down
hsa-miR-328-3p 0.040136 3.6228948 down
hsa-miR-340-5p 0.029992 2.6918004 down
hsa-miR-345-5p 3.51E-05 5.3836007 down
hsa-miR-34a-5p 0.025859 13.125367 down
hsa-miR-3613-5p 0.017127 3.2169964 down
hsa-miR-361-3p 0.018605 9.009385 down
hsa-miR-3615 0.006715 6.562682 down
hsa-miR-361-5p 0.011483 5.7131467 down
hsa-miR-365a-3p 0.024084 2.3433483 down
hsa-miR-374a-5p 0.001147 2.4867918 down
Table 5B: miRNA differentially expressed in the two PBL groups (BL-related versus EMPC-related)
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Key cellular signaling pathways and metabolic 
activities may be affected by deregulated cellular 
and viral miRNA
To explore the potential involvement of the detected 
miRNA in PBL pathogenesis, we searched for genes 
targeted by the miRNA discriminating the molecular 
subtypes of PBL that were previously confirmed as direct 
targets biochemically. Among others, we found genes 
encoding for tumor suppressors (PTEN, PBX2) and lipid 
metabolism controller (PPARGC1A, PLIN2/adipophilin) 
whose expression levels were found to be regulated by 
BART-19-5p, and FOXK2, a gene involved in the control 
of viral and cellular promoter elements, regulated by hsa-
miR148a-5p, has-miR-3609, has-miR-365. 
The expression level of the encoded proteins was 
then checked by immunohistochemistry in 13 PBL cases. 
BL-related cases presented with significantly higher 
degree of expression of PTEN, PBX2, PPARGC1A, 
PLIN2/adipophilin and FOXK2 (Figure 6A-6E and) 
(p<0.05).
We also investigated the potential pathobiological 
relevance of these genes by gene set enrichment analysis 
(GSEA). We found several gene sets significantly 
enriched; among others those associated to Kruppel-
like factor 1 (KLF1), enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) and MYC appeared 
hsa-miR-374b-5p 7.10E-04 3.1539128 down
hsa-miR-378a-3p 0.010879 59.125725 down
hsa-miR-378d 0.007875 3.1539128 down
hsa-miR-381-3p 0.015433 2.122426 down
hsa-miR-423-3p 0.01819 64 down
hsa-miR-425-5p 0.025742 10.146127 down
hsa-miR-4448 0.043389 18.01877 down
hsa-miR-454-3p 0.008394 5.0730634 down
hsa-miR-4633-5p 0.030738 49.47307 down
hsa-miR-497-5p 0.008057 4.244852 down
hsa-miR-500a-3p 0.01973 3.0920668 down
hsa-miR-502-3p 0.015503 3.031433 down
hsa-miR-574-3p 0.018238 3.9215622 down
hsa-miR-615-3p 0.032965 3.1539128 down
hsa-miR-625-3p 0.016429 7.390717 down
hsa-miR-629-5p 0.012786 3.482202 down
hsa-miR-652-3p 0.037863 7.843124 down
hsa-miR-654-3p 0.042732 2.3433483 down
hsa-miR-660-5p 0.023198 2.5365317 down
hsa-miR-664a-3p 0.007032 2.4867918 down
hsa-miR-6737-5p 0.028424 2.0400033 down
hsa-miR-92b-3p 0.004056 1747.9257 down
hsa-miR-93-5p 0.014503 56.829643 down
hsa-miR-96-5p 0.027386 3.482202 down
hsa-miR-98-5p 0.037122 3.4139185 down
hsa-miR-3178 0.025964 66.58581 up
hsa-miR-3648 0.010903 4.080006 up
hsa-miR-4492 0.037656 91768.664 up
hsa-miR-4497 0.029851 3859.7363 up
hsa-miR-4508 0.039168 1108.4174 up
hsa-miR-5787 0.01597 22492.303 up
hsa-miR-6087 0.032981 14.207409 up
hsa-miR-6126 0.001043 12.125731 up
hsa-miR-663b 0.019219 5.6011167 up
hsa-miR-6739-5p 1.33E-04 3.482202 up
hsa-miR-6743-5p 0.029317 4.594794 up
hsa-miR-7704 0.026789 62990.94 up
hsa-miR-8072 0.034227 2.0808065 up
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of particular interest due to the high scores and consistent 
recurrence (Supplementary Table 5).
Novel miRNA discovery 
We analyzed 13 PBL miRNA-seq libraries to 
identify candidate novel miRNA species that were 
deregulated in this tumor type. After sequence filtering, 
we enumerated 133 candidate novel miRNA, not 
identified in miRBase v21 (Supplementary Table 6). 
Differential expression analysis was carried out between 
PBL versus EMPC and PBL versus BL. We found 27 
miRNA differentially expressed between PBL and BL, 
and 7 between PBL and EMPC (Supplementary Tables 
7-8). Further, 17 miRNA discriminated the HIV positive 
cases from the HIV negative ones (Supplementary Table 
9). Conversely, none of the putative novel miRNA were 
differentially expressed in PBLs according to their relation 
with EMPC or BL. Of note, one of these novel putative 
miRNA mapped on the HIV genome. However, these 
preliminary observations need appropriate validation.
DISCUSSION
The pathogenesis of PBL has not been clearly 
defined but most likely it involves deregulation of terminal 
B-cell differentiation and apoptosis, via the effect of MYC 
gene rearrangements and possibly EBV infection [3]. To 
better understand the viral program expressed in PBLs, 
we performed a complete assessment of EBV-encoded 
genes and proteins, demonstrating a non-canonical 
latency-associated program with the expression of latency 
II characterizing viral proteins along with sporadic lytic 
cycle reactivation. Nonetheless, the absence of BLLF1/
gp350 expression in all the cases indicated an abortive lytic 
cycle in neoplastic cells. These results are consistent with 
previous findings, suggesting that EBV lytic reactivation 
may have pathogenic relevance in the context of both 
Figure 5: Plasmablastic lymphomas differ in their miRNA profile according to the presence of HIV. Principal component 
analysis of HIV-positive and HIV-negative plasmablastic lymphomas (PBLs) indicated a rough distinction of the two groups based on 
miRNA expression A.. Supervised analysis (T-test) comparing HIV-positive versus HIV-negative PBLs identified a series of differentially 
expressed genes B.. In the matrix, the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage 
method. In the matrix, each column represents a sample and each row represents a gene. The colour scale bar shows the relative gene 
expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). 5C. HIV-miR-367 expression in 
HIV positive and HIV negative PBL cases C.. HIV-miR-TAR-3p expression in HIV positive and HIV negative PBL cases D..
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active and depressed immune response [6]. Intriguingly, 
we have recently demonstrated a non-canonical latency 
program with activation of the lytic cycle also in endemic 
BL cases, highlighting another overlap between PBL and 
BL [7]. 
The limited knowledge on PBL biology likely 
contributes to suboptimal management and poor 
prognosis of the patients. Therefore, in the present study 
we attempted to shed new light on the molecular bases of 
PBL. We studied for the first time the miRNA expression 
profile of PBL and compared it with those of BL and 
EMPC, chosen as the closest neoplastic counterparts 
considering morphological, immunophenotypic, genetic 
and epidemiological factors. 
For the first time we observed that PBL include 
at least two molecular subgroups that presented with 
clinico-pathological peculiar features, including MYC 
rearrangements and HIV-association that appeared as 
main drivers of this sub-classification. On the other hand, 
this might be also due to a dissimilar histogenesis, genetic 
Table 6: Molecular diagnosis of PBL versus EMPC: diagnostic accuracy of the 4-miRNA based classifier in the 
discovery set
  Conventional histopathology
PBL EMPC
miRNA profiling
PBL 13 0
EMPC 0 7
  Value 95% CI
Accuracy
SP 100% 100-100
ST 100% 100-100
PPV 100% 100-100
NPV 100% 100-100
LR+ 10 1.56 to 64.20
LR- NC NC
Overall accuracy 100% (20/20)
Pre-test probability 50% 28-72
Table 7: Molecular diagnosis of PBL versus EMPC: diagnostic accuracy of the 4-miRNA based classifier in the 
validation set
Conventional histopathology
PBL EMPC
miRNA profiling
PBL 10 1
EMPC 0 9
Value 95% CI
Accuracy
SP 90% 71-100
ST 100% 100-100
PPV 91% 74-100
NPV 100% 100-100
LR+ 10 1.56 to 64.20
LR- NC NC
Overall accuracy 95% (19/20)
Pre-test probability 50% 28-72
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background and/or microenvironmental influences [5, 7, 
8]. Interestingly, we found that the two PBL subgroups 
differed for the expression of proteins, the regulation of 
which might be sustained by the differentially expressed 
miRNA. These proteins turned out to be involved in 
relevant cellular processes including cell cycle and 
proliferation, signal transduction, apoptosis, viral 
replication, cell metabolism, epigenetic regulation of 
transcription (via EZH2) and differentiation. Of note, our 
findings unveiled another overlap between PBL and BL 
related to the metabolic reprogramming of the neoplastic 
cells [9]. In fact, both PBL and BL showed an activation 
of the lipid metabolism characterized by the expression of 
adipophilin, likely related to MYC activity as previously 
reported in the B-cell setting [10, 11].
Furthermore, we identified specific differences 
between PBL and both BL and EMPC as far as miRNA 
expression was concerned. Of note, based on the 
expression of as few as 4 miRNA, we could efficiently 
perform a molecular differential diagnosis between 
Figure 6: PTEN, PBX2, PPARGC1A, PLIN2/adipophilin, and FOXK2 protein expression in the two sub-groups of 
PBL. PTEN, PBX2, PPARGC1A, PLIN2/adipophilin and FOXK2 showed lower level of expression in all the PBL cases that clustered 
closer to the EMPC cases than to the BL cases; one representative case for each sub-group is depicted. A.-E., O.M.: 40x. PBL: plasmablastic 
lymphoma; EMPC: extramedullary plasmacytoma; BL: Burkitt lymphoma.
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PBL and EMPC, even when anaplastic/plasmablastic 
EMPC were included. The latter, at present constitute 
real diagnostic challenges even for most experienced 
hematopathologists. Here, we demonstrated the efficiency 
of the molecular diagnostic tool in two independent 
cohorts of unselected cases, fulfilling the STARD criteria 
for molecular diagnostic. Phase 4 diagnostic accuracy 
studies are now warranted to prospectively evaluate the 
clinical utility of the test. 
Finally, we observed that PBL molecular features 
are at least in part dependent on HIV status. Different 
mechanisms might be in place how HIV might contribute 
to PBL pathogenesis: duration and the degree of 
immunodeficiency, loss of immune control of oncogenic 
herpesviruses as EBV, chronic B-cell proliferation/
exhaustion due to chronic antigenic stimulation, and/
or factors unrelated to immune dysfunction, including a 
theoretically possible direct oncogenic effect. Actually, the 
involvement of HIV infection in PBL pathogenesis may 
explain the high frequency of this virus in PBL patients. 
In our analysis, HIV-positive and HIV-negative PBL 
cases differed in terms of cellular miRNA. This might be 
due in part to HIV itself by its own miRNA. However, 
only when qPCR was performed we could detect very 
low amounts of HIV-encoded miRNA in PBL cases. 
This likely reflected the inferior sensitivity of RNAseq 
analysis, especially when filters improving specificity and 
robustness are applied to RNAseq analysis. Indeed, the 
detection of viral miRNA is more likely consistent with 
the hypothesis that they were encoded in scattered T-cells, 
macrophages or dendritic cells rather than in the neoplastic 
clone. Nevertheless, their potential pathogenetic role in 
PBL cannot be excluded as miRNA are easily transferred 
through the tissues in the tumor microenvironment. 
Moreover, we identified by NGS a putative novel miRNA 
mapping on the HIV genome and highly expressed by 
PBL cells, the significance of which definitely need further 
analysis. 
The major limitation of the study is probably the 
relatively low number of PBL cases analyzed (N=23). 
Nonetheless, it should be noted that all results have 
been validated in a cohort of cases independent from the 
discovery one, this making quite solid our assumptions 
[12].
In conclusion, the present study offers novel insights 
on PBL biology and pathogenesis that might be useful for 
the future management of this orphan disease in terms of 
classification, diagnosis and treatment. Particularly, an 
improved understanding of the complex interplay between 
genetic lesion and viral effects, as well as the multiple 
mechanisms regulating EBV reactivation might lead to the 
development of more specific therapies including miRNA-
targeted therapies, MYC signaling pathways inhibitors, 
and combination of EBV lytic phase induction and anti-
EBV drugs [13].
MATERIALS AND METHODS
Cases selection, immunohistochemistry, 
fluorescent in situ hybridization (FISH) and 
EBER-in-situ hybridization
For this study 23 PBL, 17 EMPC and 18 BL cases 
(9 endemic, 9 sporadic), collected at the Departments 
of Pathology of Aga Khan University Hospital, Nairobi 
(Kenya), Aga Khan Hospital, Kisumu (Kenya), Terni 
Hospital (Italy), and Siena University Hospital (Italy), 
were studied. Thirteen PBL, 7 EMPC and 9 BL (5 
endemic) cases were used as discovery cohort for NGS-
based miRNA profiling and EBV-latency assessment; 10 
PBL, 10 EMPC and 10 BL cases were used as independent 
validation set of NGS analyses and were studied by qPCR 
and immunohistochemistry. The cases were reviewed 
by expert hemato-pathologists and diagnoses were 
confirmed by morphology on histological slides stained 
with haematoxylin and eosin (H&E) and Giemsa, and by 
immunophenotyping, according to the WHO [1, 14]. The 
following clinical data were collected: age, sex, disease 
location at presentation and an associated context of 
immunodeficiency.
Immunohistochemical studies were performed 
on representative paraffin sections from each case as 
previously reported [7, 15]. A large panel of antibodies 
(CD20, PAX-5, CD38, CD138, CD79a, CD10, BCL6, 
BCL2, MUM1, CD56, Igk, Igl) was applied to assess 
plasma cell differentiation. MYC protein expression and 
the proliferative index (by Ki-67) was evaluated. To rule 
out a diagnosis of ALK-positive large B-cell lymphoma 
or diffuse large B-cell lymphoma arising in multicentric 
Castlemann disease, immunohistochemical evaluation of 
ALK protein and HHV-8 was checked as well. 
We studied the latency type of EBV by assessing 
the expression of some latent (EBNA-1, EBNA-
2, EBNA-3, LMP-1, LMP-2A) and lytic proteins 
(EA-D, EA-R, BZLF1/ZEBRA, BLLF1/gp350) by 
immunohistochemistry. In situ hybridization for the 
non-coding EBERs was carried out in each sample as 
previously described [7]. A control slide, prepared from 
a paraffin-embedded tissue block containing metastatic 
nasopharyngeal carcinoma in a lymph node, accompanied 
each hybridization run. 
In addition, the expression level of the proteins 
(adipophilin, PPARGC1A, FOXK2, PBX2, and PTEN) 
encoded by the genes found to be potentially targeted by 
the cellular and viral miRNA deregulated in the studied 
tumors was checked in the different primary tumors to 
highlight their positive or negative regulation by miRNA 
[16]. Differences in protein expression between cases 
were analyzed using the Chi-square test with p<0.05 being 
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statistical significant. 
For all the stains, negative controls were obtained 
for each case by replacing the specific antibody with 
non-immune serum immunoglobulins at the same 
concentration as the primary antibody. Sections of reactive 
lymphoid tissue and of lymph node with infectious 
mononucleosis were used as positive control for plasma 
cell differentiation and EBV latency type and lytic phase.
FISH analysis for MYC rearrangements was 
performed using both dual-fusion probes and split-signal 
probes for IGH and IGL loci as well as an LSI IGH/
MYC CEP 8 Tri-color dual-fusion probe (Vysis, Abbott 
Molecular IL, USA) [15].
All the clinical, morphological, immunophenotypical 
and cytogenetic features of the discovery cohort patients 
are summarized in Table 1. 
MicroRNA profiling
Total RNA was extracted from formalyn-fixed 
paraffed-embedded (FFPE) sections of primary tumors 
and reactive lymph nodes using the FFPE miRNA 
Easy kit (Qiagen, CA), according to the manufacturer’s 
instructions. Small RNA libraries were prepared from 1 µg 
of an high-quality RNA (RNA Integrity Number≥8) with 
the TruSeq Small RNA kit (Illumina). 1x36 sequencing 
was performed on the Illumina MiSeq platform. 36-
bp length raw sequences were demultiplexed using the 
Illumina pipeline CASAVA v1.8. A quality check of the 
run experiment was performed by FastQC (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc). Low 
quality reads and adpater sequences were trimmed off 
using Trimmomatic [17]. The high quality reads, with 
a length of 17–36-bp were clipped and subsequently 
aligned to the latest mirBase release (v 21 July 2014) 
[18] by Novoalign (http://www.novocraft.com) MiRNA 
expression profiles were built by calculating the sum of 
read counts for each miRNA, according to the alignment 
criteria. Variance-stabilizing transformed count data were 
used to build an Euclidean distance matrix, followed 
by hierarchical clustering analysis to study the intra-
samples correlations. miRNA differential expression 
analysis was performed using Bioconductor’s package 
DESeq [19]. The obtained read counts for each identified 
miRNA were first normalized by scaling for library size 
factors in order to deal with variation among samples. 
The differential expression values were estimated using a 
negative binomial distribution model and local regression 
to estimate the relationship between the dispersion and 
the mean of each miRNA. Raw values were considered as 
statistically significant for p <0.05. Following alignment 
and normalization, the data were analyzed using 
GeneSpring GX12 as previously described [20-25], by 
applying Pearson correlation (for unsupervised clustering) 
and two-tails Student t-test with p-value <0.05 and fold 
change >2 (for supervised clustering). The experimentally 
validated targets for the viral and cellular miRNA were 
searched in public databases. For the viral miRNA, we 
used VIRmiRNA (http://crdd.osdd.net/servers/virmirna/) 
[26]; for the cellular miRNA, miRWalk 2 (http://zmf.umm.
uni-heidelberg.de/apps/zmf/mirwalk2/) [27, 28]. Only 
proved direct interaction were then considered. Pathway 
analysis was performed by Gene Set Enrichment Analysis 
(GSEA) [29]. 
Reverse transcription-quantitative PCR (RT-
qPCR) 
The expression of EBV-encoded genes (EBNA-1, 
EBNA-2, LMP-1, LMP-2, EBNA-3, BZLF-1 BMRF-1/
Ea-D, BHRF-1/Ea-R, BLLF1/gp350) characterizing 
the different latency programs, has been investigated by 
RT-qPCR using the QuantiTect SYBR Green PCR Kit 
(Qiagen, CA). The stably expressed housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
was used as an endogenous control and reference gene for 
relative quantification of each target gene. The relative 
expression is expressed as 2ΔCt, where ΔCt is defined as the 
difference in mean cycle thresholds of the gene of interest 
and HPRT. 
The expression level of differentially expressed 
human (hsa-miR1304-3p, hsa-miR148a-3p, hsa-miR148a-
5p, hsa-miR192-5p) and viral miRNA (EBV-miR-BART-
10-5p, EBV-miR-BART-18-5p, EBV-miR-BART-19-3p), 
selected based on the score in differential analysis and 
the known biological relevance, was evaluated by using 
Taqman probes specific for each miRNA and for RNU6B 
(the endogenous control) (Apllied Viosystems, Applera, 
Italy). The relative expression of cellular miRNA was 
calculated using the 2-∆∆ct formula; for viral miRNA the 
following formula was adopted: 2-∆ct [30]. Primers used for 
qPCR analyses are detailed in Table 2.
Diagnostic accuracy evaluation
A diagnostic accuracy analysis was designed to 
test the ability of a newly developed molecular classifier 
(in particular of the 4-miRNAs based classifier) to 
discriminate PBL and EPCM. Calculations of sensitivity, 
specificity, positive predictive value, negative predictive 
value, positive and negative likelihood ratio, and odd ratio 
were made by CATmaker software (Centre for Evidence 
Based Medicine, Oxford University, http://www.cebm.
net). The study was conducted according to the STARD 
guidelines for biomarker testing (Supplementary Table 1).
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